PATENT CLAIM ANALYSIS

Application Number: 16052791
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["544", "280000"]

Abstract:
The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Claim (Index 12):
The compound according to  claim 1  is or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 96.0
- Lexical Diversity: 1.32558
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15114857', '13820184', '13498975', '15114858', '15927920']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8149782630011413
- 35 USC 102 Novelty (BERT): 0.5471989213086816
- Combined Prediction Score: 0.7882003288318953
- Mean Citation Score: 366.327656
- Max Citation Score: 409.61624
- Similarity Product: 341.166114057684

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test